Reactive Metabolite Detection Studies: Cysteine Trapping by Xenotech
Drug-induced liver injury (DILI) is caused by various mechanisms, so combining several experiments into a comprehensive score gives more accurate risk assessment. Covalent binding for reactive metabolite detection improves selectivity and specificity but needs a radiolabeled test article, unsuitable for early development; glutathione (GSH) trapping is often used instead but can be costly, lower-throughput or less quantitative.
The cysteine trapping study developed by SEKISUI’s Drug Development Solutions Center (DDSC) is more quantitative, with higher throughput and lower cost.
Speaker
Miki Fujishima
Assistant Manager, Business Development | Drug Development Solutions Center (SEKISUI), Tokai, Japan
Miki Fujishima facilitates ADME solutions for clients and works with R&D scientists to develop and improve liver-toxicity assays. She received her master’s degree in Drug Metabolism and Molecular Toxicology from Tokyo University of Pharmacy and Life Sciences in 2007 and joined the Drug Development Solutions Center that year, helping establish drug transporter studies at Tokai and SEKISUI XenoTech before specialising in DMPK test systems, including hepatocytes and subcellular fractions.
Key Learning Objectives
- The relation between DILI and reactive metabolites
- Evaluating reactive metabolites, with a relevant case study
- Comparison of GSH and cysteine trapping evaluation methods
- Cysteine trapping study design, assay procedure and comparative data
Watch Now: Reactive Metabolite Detection Studies: Cysteine Trapping by Xenotech
This webinar is available on demand. Fill in the form to watch the full recording — we'll email you the link too.
- January 27, 2022
- Miki Fujishima, Drug Development Solutions Center (SEKISUI), Tokai, Japan
- kbiinfo@krishgen.com
- +91 22 49198700
Your details
Request the recording
Fill in your details and we'll email you the recording.
More Webinars
Shortcuts to Discovery and Characterization of Monoclonal Antibodies
Monoclonal antibody (mAb) discovery and characterization often face significant delays due to iterative screening cycles, late-stage functional failures, and downstream analytical bottlenecks. This webinar details five practical shortcuts that accelerate timelines from target validation to preclinical characterization.
View Webinar June 12, 2026Viral Vectors & CRISPR for Building Disease Models
Gene editing and viral vector technologies are transforming the development of advanced disease models for translational research.
View Webinar April 17, 2026Advanced Immunocompetent Primary Human Airway Models for Respiratory Disease Modeling
Advancements in human-relevant in vitro models are transforming how respiratory diseases are studied and how drug safety and efficacy are evaluated.
View Webinar